These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24900525)

  • 1. Monitoring the distribution of warfarin in blood plasma.
    Rosengren AM; Karlsson BC; Nicholls IA
    ACS Med Chem Lett; 2012 Aug; 3(8):650-2. PubMed ID: 24900525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions between warfarin and psychotropics: updated review of the literature.
    Nadkarni A; Oldham MA; Howard M; Berenbaum I
    Pharmacotherapy; 2012 Oct; 32(10):932-42. PubMed ID: 23033232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of hepatic uptake on the disappearance of warfarin from the plasma of rats: a kinetic analysis.
    Covell DG; Abbrecht PH; Berman M
    J Pharmacokinet Biopharm; 1983 Apr; 11(2):127-45. PubMed ID: 6886970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How warfarin's structural diversity influences its phospholipid bilayer membrane permeation.
    Karlsson BC; Olsson GD; Friedman R; Rosengren AM; Henschel H; Nicholls IA
    J Phys Chem B; 2013 Feb; 117(8):2384-95. PubMed ID: 23373529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norfloxacin does not alter warfarin's disposition or anticoagulant effect.
    Rocci ML; Vlasses PH; Distlerath LM; Gregg MH; Wheeler SC; Zing W; Bjornsson TD
    J Clin Pharmacol; 1990 Aug; 30(8):728-32. PubMed ID: 2401751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin: an environment-dependent switchable molecular probe.
    Nicholls IA; Karlsson BC; Rosengren AM; Henschel H
    J Mol Recognit; 2010; 23(6):604-8. PubMed ID: 21031478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ detection of warfarin using time-correlated single-photon counting.
    Rosengren AM; Karlsson BC; Näslund I; Andersson PO; Nicholls IA
    Biochem Biophys Res Commun; 2011 Apr; 407(1):60-2. PubMed ID: 21354105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials.
    Amin A; Deitelzweig S; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Thromb Thrombolysis; 2014; 38(2):150-9. PubMed ID: 24477787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
    Palareti G; Legnani C
    Clin Pharmacokinet; 1996 Apr; 30(4):300-13. PubMed ID: 8983860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin resistance with nafcillin therapy.
    Qureshi GD; Reinders TP; Somori GJ; Evans HJ
    Ann Intern Med; 1984 Apr; 100(4):527-9. PubMed ID: 6703546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial.
    Garrison SR; Green L; Kolber MR; Korownyk CS; Olivier NM; Heran BS; Flesher ME; Allan GM
    Ann Fam Med; 2020 Jan; 18(1):42-49. PubMed ID: 31937532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible potentiation of warfarin by fluconazole.
    Seaton TL; Celum CL; Black DJ
    DICP; 1990 Dec; 24(12):1177-8. PubMed ID: 2089826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
    Zivelin A; Rao LV; Rapaport SI
    J Clin Invest; 1993 Nov; 92(5):2131-40. PubMed ID: 8227329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro amiodarone protein binding and its interaction with warfarin.
    Neyroz P; Bonati M
    Experientia; 1985 Mar; 41(3):361-3. PubMed ID: 3972082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate potentiates warfarin effects.
    Kim KY; Mancano MA
    Ann Pharmacother; 2003 Feb; 37(2):212-5. PubMed ID: 12549950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprothrombinemia as a result of a possible warfarin and intravaginal miconazole interaction.
    Thomas JL; Dunn D; Pelletier A; Franks AS
    South Med J; 2010 Oct; 103(10):1063-5. PubMed ID: 20802381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition.
    Wu S; Chen X; Jin DY; Stafford DW; Pedersen LG; Tie JK
    Blood; 2018 Aug; 132(6):647-657. PubMed ID: 29743176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of sampling on the determination of warfarin and warfarin alcohols in oral fluid.
    Lomonaco T; Ghimenti S; Piga I; Biagini D; Onor M; Fuoco R; Di Francesco F
    PLoS One; 2014; 9(12):e114430. PubMed ID: 25478864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial.
    Yuan CS; Wei G; Dey L; Karrison T; Nahlik L; Maleckar S; Kasza K; Ang-Lee M; Moss J
    Ann Intern Med; 2004 Jul; 141(1):23-7. PubMed ID: 15238367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.